These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22609816)

  • 21. Effect of sertindole on QTc interval in patients with schizophrenia.
    Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
    Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do we need another atypical antipsychotic?
    Kasper S
    Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the efficacy, tolerability and safety of sertindole in clinical trials.
    Perquin L; Steinert T
    CNS Drugs; 2004; 18 Suppl 2():19-30; discussion 41-3. PubMed ID: 15461313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy.
    Wehnert A
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sertindole for the treatment of schizophrenia.
    Azorin JM; Kaladjian A; Fakra E; Adida M
    Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sertindole in schizophrenia: a clinical review.
    Zoccali RA; Bruno A; Muscatello MR
    J Clin Psychopharmacol; 2015 Jun; 35(3):286-95. PubMed ID: 25830594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
    Kasper S; Möller HJ; Hale A
    Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.
    van Kammen DP; McEvoy JP; Targum SD; Kardatzke D; Sebree TB
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):168-75. PubMed ID: 8935813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
    Thomas SH; Drici MD; Hall GC; Crocq MA; Everitt B; Lader MH; Le Jeunne C; Naber D; Priori S; Sturkenboom M; Thibaut F; Peuskens J; Mittoux A; Tanghøj P; Toumi M; Moore ND; Mann RD
    Acta Psychiatr Scand; 2010 Nov; 122(5):345-55. PubMed ID: 20384598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sertindole versus haloperidol for schizophrenia.
    Balon R
    Am J Psychiatry; 1998 Sep; 155(9):1303-4. PubMed ID: 9734566
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.
    Kwon JS; Mittoux A; Hwang JY; Ong A; Cai ZJ; Su TP
    Int Clin Psychopharmacol; 2012 Nov; 27(6):326-35. PubMed ID: 22850268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia.
    Buchsbaum MS; Haznedar M; Newmark RE; Chu KW; Dusi N; Entis JJ; Goldstein KE; Goodman CR; Gupta A; Hazlett E; Iannuzzi J; Torosjan Y; Zhang J; Wolkin A
    Schizophr Res; 2009 Oct; 114(1-3):161-71. PubMed ID: 19695836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The atypical antipsychotic sertindole: a case series.
    Lee AM; Knoll JL; Suppes T
    J Clin Psychiatry; 1997 Sep; 58(9):410-6; quiz 417-8. PubMed ID: 9378698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The experience of using the atypical antipsychotic sertindole in psychiatric inpatient clinics in Russia].
    Ivanets NN; Kinkul'kina MA; Avdeeva TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(6):37-41. PubMed ID: 21716249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the safety and tolerability of sertindole.
    Hale AS
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S65-70. PubMed ID: 9690973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
    Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.